Research output per year
Research output per year
Fingerprint
Dive into the research topics where Rudy Schreiber is active. These topic labels come from the works of this person. Together they form a unique fingerprint.
- 1 Similar Profiles
Research output
-
EAAT3 modulation: A potential novel avenue towards remyelination in multiple sclerosis
van Veggel, L., Schepers, M., Tiane, A., Kumar, V., Willems, E., Rombaut, B., Noordijk, J., Vangansewinkel, T., Li, A., Wolfs, E., Ozcan, B., Nouboers, E., Moya, P. R., Sauer, D. B., Diliën, H., Hellings, N., Schreiber, R. & Vanmierlo, T., May 2025, In: Biomedicine & Pharmacotherapy. 186, 18 p., 117960.Research output: Contribution to journal › Article › Academic › peer-review
Open Access -
Harnessing brain-derived extracellular vesicles to support RDoC-based drug development
Magaraggia, I., Krauskopf, J., Ramaekers, J. G., You, Y., de Nijs, L., Briedé, J. J. & Schreiber, R., 1 Jan 2025, In: Neuroscience Applied. 4, 16 p., 105406.Research output: Contribution to journal › (Systematic) Review article › peer-review
Open Access -
Connecting the Dots in Translational Neuroscience
Schreiber, R., 2024, Modern CNS Drug Discovery: Novel Therapeutics for Psychiatric and Neurological Diseases: from Target Identification to Regulatory Approval. Schreiber, R. (ed.). 2 ed. Springer, p. 209-213 5 p.Research output: Chapter in Book/Report/Conference proceeding › Chapter › Academic
-
From Scientists to Innovators for Industry: An European Program Addressing the Workforce Challenge in the Pharma Industry
Broy, J., Schreiber, R. & Govers, M., 2024, Modern CNS Drug Discovery: Novel Therapeutics for Psychiatric and Neurological Diseases: from Target Identification to Regulatory Approval. R. S. (ed.). 2 ed. Springer, p. 31-48 18 p.Research output: Chapter in Book/Report/Conference proceeding › Chapter › Academic
-
Innovator, Entrepreneur, Leader: The Tripartite Drug Discovery Neuroscientist
Schreiber, R., Govers, M. & Van der Lugt, A., 2024, Modern CNS Drug Discovery: Novel Therapeutics for Psychiatric and Neurological Diseases: from Target Identification to Regulatory Approval. R. S. (ed.). 2 ed. Springer, p. 9-29 21 p.Research output: Chapter in Book/Report/Conference proceeding › Chapter › Academic